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Spinal tuberculosis (TB) accounts for ~2 - 4% of all tuberculosis 
cases and is the most common form of musculoskeletal TB.[1,2] The 
condition involves gradual destruction of one or more spinal vertebrae 
following haematogenous spread of Mycobacterium tuberculosis from 
a primary focus and typically manifests as gradually worsening back 
pain, with or without constitutional symptoms.[3-6] Progression of the 
disease is associated with significant morbidity, with previous reports 
suggesting spinal deformity in 16 - 77% of cases and neurological 
deficits due to compression of the spinal cord in 33 - 73%.[4-7] Early 
diagnosis and adequate TB treatment are key factors in optimising 
outcomes.[5]
Western Cape Province, South Africa (SA), has one of the highest 
burdens of TB worldwide, with 681 notified cases per 100 000 
population and an HIV co-infection rate of 38.5% in 2015.[8] In this 
setting, spinal TB is comparatively common, with at least 393 cases 
seen at tertiary hospitals in the province between 2012 and 2015 
and an estimated incidence of 1.22 - 2.57 cases per 100  000 over 
this period.[7] Drug-resistant spinal TB was established in 9% of 
cases.[7] While health policy specifically addressing spinal TB is 
currently lacking, established practice in the province has been to 
refer patients with suspected spinal TB to specialist orthopaedic 
services for diagnosis, including an in-theatre spine biopsy.[3,7] TB 
treatment is typically initiated in hospital and then continued at a 
local primary healthcare clinic upon discharge. Patients are treated 
with a combination preparation of rifampicin, isoniazid, ethambutol 
and pyrazinamide throughout the course of treatment, although this 
approach is informed by clinical experience rather than controlled 
trials.[3]
The appropriate length of treatment for spinal TB remains a 
contentious issue, as discussed in detail elsewhere.[3,9-11] Although 
certain studies have suggested that 6 months of treatment is effective, 
most treating orthopaedic specialists continue to report at least 
9 - 12  months of treatment.[9,11] Furthermore, advanced imaging 
over the course of treatment has suggested substantial variation in 
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Background. Patients diagnosed with spinal tuberculosis (TB) at a major tertiary hospital in Western Cape Province, South Africa, are 
required to attend regular follow-up at the hospital’s outpatient spine clinic and to remain on TB treatment for at least 9 months. This follow-
up and lengthy treatment is intended to allow for specialist monitoring of TB treatment response and early identification of secondary 
complications, and to reduce the risk of recurrence. However, little is known about adherence to these recommendations.
Objectives. The main objectives were to describe (i) loss to spine clinic follow-up (LTFU), and (ii) TB treatment duration among patients 
diagnosed with spinal TB at the hospital. Secondary objectives were to investigate (i) the association between LTFU and treatment duration, 
and (ii) factors associated with LTFU.
Methods. This retrospective cohort study included 173 adults diagnosed with spinal TB between 2012 and 2015 and investigated follow-up 
within 2 years from diagnosis. Clinical, demographic and appointment data were obtained from hospital records and a dataset provided by 
the provincial Department of Health. LTFU was presented as frequency (%) and as a survival analysis. TB treatment duration was reported 
as frequency <9 months or ≥9 months, and the association between LTFU and <9 months of treatment was investigated using relative risk 
(RR) with 95% confidence intervals (CIs). Univariate associations between explanatory variables and LTFU were investigated using simple 
logistic regression analysis.
Results. Patients had a median (interquartile range) age of 36 (29 - 48) years and included 98 females (57%) and 151 individuals (87%) 
residing <50 km from the hospital. Primary outcomes were that 129 patients (75%) were LTFU within 2 years of diagnosis and 45 (30%) 
completed <9 months of treatment. The RR of <9 months of treatment was 1.62 (95% CI 1.39 - 1.88) among those LTFU compared with 
those retained in follow-up. LTFU was not associated with any of the clinical or demographic variables investigated.
Conclusions. Three-quarters of the patients did not complete follow-up at the tertiary hospital spine clinic, and almost one in three received 
<9 months of TB treatment. Remaining in spine clinic follow-up was significantly associated with receiving at least the minimum duration 
of TB treatment. However, LTFU could not be predicted from routine clinical and demographic information and is likely to be related to 
factors not accounted for in the current analysis.
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the time to apparent clinical cure in spinal TB, with most patients 
showing unresolved spinal lesions at 9 months of treatment.[12-14] In 
the absence of convincing evidence for shorter regimens, orthopaedic 
specialists in the Western Cape have continued to prescribe a 
minimum of 9 months of treatment for patients with spinal TB, based 
on clinical experience and historical teaching.[3,10,15] Furthermore, the 
established standard of care has been for patients to attend follow-up 
at the tertiary hospital’s outpatient spine clinic every 3 - 4 months 
over the course of treatment, over and above monthly visits to their 
local primary healthcare clinic.
In the current high-burden, resource-limited setting, routine 
advanced imaging to assess clinical cure in spinal TB is not 
feasible. However, serial follow-up at the spine clinic allows for 
monitoring of treatment response using clinical improvement, 
the erythrocyte sedimentation rate (ESR) and signs of healing 
on a spine radiograph. [10,15] While these measures cannot reliably 
establish clinical cure, they are used to assess for a trend of healing. 
Furthermore, the visits are used to ensure that patients complete the 
extended period of treatment and to monitor for any progression of 
deformity or late neurological changes. After the minimum 9 months 
of treatment, the decision to terminate or continue TB treatment 
is made on an individual level based on the clinical judgement of 
the specialist.[10] Treatment is stopped by the specialist providing 
the patient with a letter to the clinic to this effect, and patients are 
typically requested to attend one final spine clinic visit 3 months 
post treatment to ascertain whether there has been any recurrence of 
symptoms or notable increase in the ESR.
In the event of drug-resistant spinal TB, an appropriate regimen 
and duration are determined by infectious disease specialists. 
However, patients with drug resistance attend follow-up at both the 
spine clinic and the infectious diseases clinic and are monitored using 
the same measures as used in drug-sensitive spinal TB. The decision 
to terminate treatment is made in collaboration with infectious 
disease specialists, based on clinical judgement.
It is envisaged that spine clinic follow-up plays an important 
role in providing adequate care for patients with spinal TB. While 
necessary treatment duration is likely to vary between individuals, 
extended treatment serves to err on the side of caution in the 
absence of a marker of clinical cure. Specialist follow-up facilitates 
clinical monitoring and may help to ensure completion of extended 
treatment, whereas patients lost to follow-up may stop treatment 
prematurely, potentially increasing the risk of recurrence, further 
pathology and a renewed burden on the health system. However, 
there are several factors that may impact on patient willingness 
and ability to attend spine clinic follow-up, including the lengthy 
follow-up period, the time and expense of travel to the hospital, 
the discomfort of travel for this particular patient group, and the 
concurrent monthly local clinic visits.
Although spine clinic follow-up and extended treatment for spinal 
TB is a longstanding practice in the current setting, little is known 
about adherence to this follow-up or about treatment duration in 
practice. Previous TB-related studies have reported on continuity 
of care between hospital-diagnosed TB cases and primary care,[16-19] 
loss to follow-up from TB treatment at primary healthcare level[20-23] 
and adherence to TB treatment.[24-28] However, there appears to be 
little existing literature addressing tertiary hospital follow-up as part 
of care for a TB episode. Previous studies investigating hospital-
based follow-up in orthopaedics have for the most part focused on 
trauma follow-up in a developed country setting, including well-
resourced clinical trials.[29-34] Although Dunn et al.[15] alluded to poor 
compliance with tertiary hospital follow-up among spinal TB patients 
in the Western Cape, this concern fell beyond the main objective of 
the present study and was not subsequently investigated.
Objectives
The main objectives of the present study were to describe (i) loss to 
spine clinic follow-up (LTFU), and (ii) TB treatment duration among 
patients diagnosed with spinal TB at a major tertiary hospital in 
the Western Cape. Secondary objectives were to investigate (i) the 
association between LTFU and treatment duration, and (ii) baseline 
variables associated with LTFU. It was envisaged that insight into 
the extent of LTFU among patients with spinal TB and the relevant 
risk factors could help to inform health systems strengthening for 
the treatment of this severe TB disease as well as other conditions 
requiring tertiary hospital follow-up.
Methods
Study design and population
A retrospective cohort study was conducted, with all adults (age 
≥15 years) diagnosed at a single tertiary hospital between 1 January 
2012 and 31 December 2015 systematically selected for inclusion. 
These patients formed part of a larger, finite population of 319 adults 
diagnosed with spinal TB at tertiary hospitals in the Western Cape 
over the 4-year period, with further details of case identification 
and diagnosis described elsewhere.[7] This lengthy study period and 
systematic inclusion of patients was necessary, given the compara-
tively low incidence of spinal TB.[7] The follow-up period was 2 years 
from diagnosis to allow for 9 - 18 months of treatment plus the 
standard post-treatment assessment.
Exclusion criteria for the study were management by a specialty 
other than orthopaedic spinal services, moving away upon inpatient 
discharge, or death within 5 months of inpatient discharge. Patients 
managed by other specialties or who moved away upon discharge 
were never scheduled for spine clinic follow-up and therefore 
could not be evaluated for the primary outcome. Patients who died 
shortly after discharge were excluded on the basis that they did not 
contribute insight into follow-up or the relationship between follow-
up and treatment duration. Finally, cases in which it was unclear from 
the available data whether the patient was discharged or LTFU were 
also excluded, as these patients could not be reliably assigned to an 
outcome category. Characteristics of patients for whom discharge/
LTFU were unclear were presented separately.
Setting
The study took place at a major tertiary referral hospital serving 
approximately half the Western Cape, including a portion of the City 
of Cape Town Metro and certain rural districts, a catchment area of 
at least 3.4 million people.[35] The hospital provided the only public 
health sector specialist spine services in its catchment area, resulting 
in a considerable burden on service provision and considerable 
travelling distance for certain referral areas.
Data collection
Clinical and demographic data as well as details of TB treatment 
and appointments attended were accessed from a combination of 
hospital sources and a health dataset obtained from the Western 
Cape Department of Health. Hospital sources included patient 
medical records, whereas the dataset included routine information 
from the patient administration system, pharmacy records and 
the Electronic Tuberculosis Register (ETR.net) or Electronic Drug 
Resistant Tuberculosis Register. The time period for the dataset 
was 1 January 2012 - 31 December 2017. Finally, distance from the 
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hospital was taken as the shortest distance by 
road between the patient’s area of residence 
and the hospital according to Google 
Maps[30,34] and reported as both a continuous 
variable and a categorical variable, < or 
≥50 km. All study data were captured by a 
single investigator using custom-designed 
electronic data capture forms in order to 
optimise data quality and consistency.
Loss to follow-up
The definition of loss to follow-up may 
have a large impact on study findings and 
should be kept consistent between studies 
wherever possible.[36,37] However, existing 
definitions such as loss to follow-up from 
TB treatment[38] and loss to follow-up in 
orthopaedic trauma[29,31,32,34] were not suitable 
for the current context. The following 
definition was therefore developed, based 
on the expected frequency of visits.[36] Loss 
to spine clinic follow-up (LTFU) among 
patients with spinal TB was defined as 
absence from the spine clinic for at least 
6 months (180 days), including at least 
one missed appointment. This definition 
detected patients who were not monitored 
at the clinic as frequently as required and 
was approximately equivalent to two missed 
visits.
To determine LTFU, time between 
appointments was screened for periods of 
≥6 months. Periods of ≥6 months were 
subsequently investigated for missed 
appointments, as identified from the patient 
administration system or the follow-up plan 
documented in the medical record. The 
date of LTFU was recorded as the date of 
the missed appointment for patients with 
scheduled appointments[36] and the hospital 
inpatient discharge date when no spine 
clinic appointment had been booked. Data 
capture included whether patients LTFU 
returned to the spine clinic within 2 years 
of diagnosis. Patients who were not LTFU 
were described as having been retained in 
spine clinic follow-up. This group included 
patients who were discharged from the spine 
clinic and patients who remained in spine 
clinic follow-up 2 years after diagnosis. The 
duration of follow-up was calculated from 
the date of the magnetic resonance imaging 
scan, the first step in formal diagnosis of 
spinal TB, to LTFU or spine clinic discharge 
as applicable.
Treatment duration
Treatment duration was calculated as the 
difference between the start and termination 
of treatment dates and categorised as 
<9  months or ≥9 months of TB treatment. 
The start and termination of TB treatment 
were determined based on the best available 
evidence, according to the following hier-
archy: medical records, pharmacy records 
or the ETR.net. Additional treatment data 
extracted included whether or not TB 
treatment was terminated by an orthopaedic 
specialist and treatment outcome recorded 
in the ETR.net.
Data analysis
Categorical variables were presented as 
frequency (%), whereas continuous data 
with a non-parametric distribution were 
reported as medians and interquartile 
ranges (IQRs). Primary outcomes LTFU 
and treatment duration <9 months were 
presented as frequency. Furthermore, LTFU 
was also presented as a Kaplan-Meier 
survival analysis of all included patients. 
Patients discharged from the spine clinic 
were censored from survival analyses at 
discharge, and follow-up was limited to 
2 years from diagnosis for all patients.
The association between LTFU and 
<9 months of TB treatment was investigated 
by calculating the relative risk (RR) and 
associated 95% confidence intervals (CIs). 
In addition, a separate survival analysis was 
presented for patients completing <9 months 
and ≥9 months of TB treatment, and survival 
curves were compared using a log-rank test. 
Univariate relationships between explanatory 
variables and LTFU were investigated 
using a χ2 test or Fisher’s exact test for 
categorical variables and simple logistic 
regression analysis for continuous variables. 
Explanatory variables associated with LTFU 
at p≤0.20 were eligible for inclusion in the 
logistic regression model to predict LTFU 
and were reported as crude and adjusted 
odds ratios with 95% CIs. All statistical 
analyses were performed in Graphpad Prism 
version 6.00 (GraphPad Software Inc., USA) 
or Stata version 15 (StataCorp, USA) with 
significance accepted at p<0.05. Reporting 
of study findings was guided by the STROBE 
checklist for observational studies.[39]
Ethical considerations
The study was approved by the Health 
Research Ethics Committee of Stellenbosch 
University (ref. no. N15/07/062), the Provin-
cial Health Research Committee (ref. no. 
WC_201801_014) and the management of 
the hospital.
Results
Patient characteristics
Of 199 adult patients diagnosed with spinal 
TB at the hospital between 2012 and 2015, 
26 were excluded from further analysis, 
as described in Fig. 1. The remaining 173 
patients were included in the LTFU analysis, 
with the characteristics of included patients 
presented in Table 1. The 7 patients with 
discharge/LTFU unclear had a median (IQR) 
age of 35 (22 - 58) years and comprised 
4  males and 3 females, with 5 from urban 
areas and 2 from rural areas. Two patients 
Did not return 
to spine clinic,
n=92
Diagnosed with spinal tuberculosis 
at the hospital, 2012 - 2015,
N=199
Managed by different specialty, n=10*
Died shortly after discharge, n=8†
Moved away upon discharge, n=1
Intended to follow up at 
hospital spine clinic,
n=180
Discharged/lost to spine clinic 
follow-up: unclear,
n=7
Included in spine clinic 
follow-up analysis,
n=173
Retained in spine 
clinic follow-up,
n=44
Discharged,
n=17
Transferred,
n=3
Still in follow-up 
at 2 years,
n=24
Lost to spine clinic 
follow-up,
n=129
Returned to 
spine clinic, 
n=37
Fig. 1. Overview of patients included in spine clinic follow-up analysis and follow-up outcomes. 
(*Nine patients were managed by neurosurgery and one by abdominal surgery; †Median time from 
discharge to death 5 weeks, range 0 - 20 weeks.)
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received corrective surgery and 5 minor procedures, with 1 patient 
HIV-infected, 3 HIV-negative and 3 with HIV status unknown. 
The small number of patients with a missing spine clinic outcome 
precluded valid statistical comparison with those included in the 
LTFU analysis. However, no obvious differences were observed in 
these or other characteristics.
Spine clinic loss to follow-up
Of the 173 patients included in the analysis, 129 (75%) were LTFU 
within 2 years of diagnosis (Fig. 1). Although 37 patients (29%) who 
met the criteria for LTFU returned to the spine clinic for at least 
one further appointment within 2 years of diagnosis (median (IQR) 
absence 8 (7 - 11) months), 92 (71%) had no further spine clinic 
contact (Fig. 1). When examining how the percentage of patients 
in spine clinic follow-up decreased over time, the pattern showed a 
relatively steady attrition, with a median duration of 11 months in 
spine clinic follow-up (Fig. 2A) and a median (IQR) of 3 (1 - 5) spine 
clinic appointments over the 2 years. Incidental findings included 
5 patients who were, erroneously, not booked for spine clinic follow-
up at inpatient discharge. Furthermore, of the 129 patients LTFU, 42 
(33%) had a follow-up appointment indicated in the clinical records 
but no appointment booked on the patient administration system.
TB treatment
There were 150 patients for whom treatment start and end could 
be established, with the distribution of treatment duration shown 
in Fig.  3. Overall, there were 45 patients (30%) who completed 
<9 months of treatment (Table 2). Of 54 patients who had treat ment 
stopped by an orthopaedic specialist, 28 went on to complete one or 
more post-treatment spine clinic visits prescribed by the specialist, 
whereas 26 were LTFU after stopping treatment and did not return for 
the post-treatment visit (Table 2). In the ETR.net, 121 patients (70%) 
Table 1. Demographic and clinical characteristics of patients followed up at the spine clinic, in total and by follow-up outcome
Total (N=173) LTFU (N=129) Retained (N=44) LTFU v. retained, p-value
Age (years), median (IQR) 36 (29 - 48) 38 (32 - 50) 36 (28 - 47) 0.11
Sex, n (%)
Male 75 (43) 58 (45) 17 (39) 0.46
Female 98 (57) 71 (55) 27 (61)
Residence, n (%)
Urban 139 (80) 101 (78) 38 (86) 0.25
Rural 34 (20) 28 (22) 6 (14)
Travel distance (km), n (%)
<50 151 (87) 110 (85) 41 (93) 0.17
≥50 22 (13) 19 (15) 3 (7)
HIV status, n (%)
Positive 73 (42) 57 (44) 16 (36) 0.59
Negative 84 (49) 61 (47) 23 (52)
Unknown 16 (9) 11 (9) 5 (11)
Previous TB episode, n (%)
≥1 15 (9) 12 (9) 3 (7) 1.00
None 156 (90) 117 (91) 39 (89)
Unknown 2 (1) 0 2 (5)
Spinal TB diagnosis, n (%)
Bacteriologically confirmed 130 (75) 97 (75) 33 (75) 0.98
Clinically diagnosed 43 (25) 32 (25) 11 (25)
Drug susceptibility, n (%)
Sensitive 115 (66) 85 (66) 30 (68) 0.98
Mono- or multidrug resistant 13 (8) 10 (8) 3 (7)
Unknown 45 (26) 34 (26) 11 (25)
Vertebrae affected, n (%)
1 - 2 97 (56) 74 (57) 23 (52) 0.56
≥3 76 (44) 55 (43) 21 (48)
Spine deformity, n (%)
Kyphosis 133 (77) 97 (75) 36 (82) 0.37
No kyphosis 40 (23) 32 (25) 8 (18)
Surgery, n (%)
Minor procedure/none 143 (82) 106 (82) 37 (80) 0.77
Corrective surgery 30 (18) 23 (18) 9 (20)
Discharge pathway, n (%)
Discharged home 121 (70) 92 (71) 29 (66) 0.62
Admitted to secondary health facility 52 (30) 37 (29) 15 (34)
LTFU = lost to follow-up from the spine clinic; Retained = retained in follow-up at the spine clinic; IQR= interquartile range; TB = tuberculosis.
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were recorded as extrapulmonary TB and 9 
(5%) as pulmonary TB, with this information 
missing for the remaining 43 patients (25%). 
No ETR.net treatment outcome was recorded 
for 104 patients (60%), with 63 others (36%) 
recorded as ‘treatment completed’, 4 (2%) as 
‘cured’, 1 (<1%) as ‘died’ and 1 (<1%) as ‘still 
on treatment’. There was no difference in age 
(p=0.91), sex (p=0.64), HIV status (p=0.78), 
surgery (p=0.56) or LTFU (p=0.32) between 
the patients for whom treatment duration 
could be established and the 23 patients with 
missing treatment duration data. However, 
there was a significant association between 
missing treatment duration data and residing 
in a rural district (n=25, 17% v. n=9, 39%; 
p=0.02).
Spine clinic follow-up v. TB  
treatment duration
LTFU was associated with an increased risk 
of premature treatment cessation compared 
with retention in spine clinic follow-up 
(RR 1.62; 95% CI 1.39 - 1.88). Furthermore, 
all 45 patients who completed <9 months 
of treatment were patients who had been 
LTFU (Table 2). There was also a significant 
difference in the pattern of LTFU between 
those completing <9 and ≥9 months of TB 
treatment, with a median time in spine 
clinic follow-up of 5 months and 16 months, 
respectively (p<0.0001) (Fig. 2B).
Univariate and multivariate associa-
tions with LTFU
There were no significant univariate associa-
tions between LTFU and the clinical or 
demographic variables in Table 1 at p<0.05, 
or an association between LTFU and 
kilometres of travel to the hospital (p=0.21) 
or year of admission (p=0.86). Age and 
travel distance ≥50 km were entered into a 
logistic regression model based on p≤0.20, 
but the model was not statistically significant 
(p=0.10) and prediction of LTFU from the 
available variables was not investigated 
further.
Discussion
The first finding of the study was that 75% 
of patients with spinal TB were LTFU within 
2 years of diagnosis. This result suggests 
that the majority of patients did not receive 
the current standard of care in terms of 
specialist monitoring, including assessment 
of treatment response and management 
of secondary complications. Although 
some patients returned for at least one 
further appointment, the potential impact 
of LTFU remained in that patients were 
typically without spine specialist care for 
7 - 11 months and may have experienced 
worsening pathology over this period. 
Furthermore, most patients had no further 
contact with the spine clinic once LTFU and 
therefore discontinued all spine specialist 
care before being deemed clinically ready 
to do so.
The second finding of the study was that 
30% of patients with spinal TB received less 
than the 9 months minimum recommended 
treatment duration. In practice, the necessary 
duration of TB treatment is likely to vary 
between individuals.[12,14] However, it is 
challenging to confirm clinical cure in spinal 
TB, and treatment is frequently extended 
to 12 months or even more for patients 
remaining in orthopaedic follow-up. [3,14] 
This prolonged treatment is supported 
by advanced imaging studies[12-14] and is 
intended to allow for adequate antibiotic 
penetration of dead bone tissue, abscesses 
and granulomas as well as effective treatment 
in patients who are malnourished or HIV-
infected – a common concern in the SA 
public health setting.[3] Premature cessation 
of TB treatment may place individuals at 
increased risk of disease recurrence, which 
in turn risks additional spine pathology and 
further hospital admissions, scans, surgery 
and treatment. Given these implications for 
both the patient and the health system, the 
finding that almost one in three patients 
received relatively short courses of TB 
treatment presents a considerable concern.
Another pertinent finding from the 
current study was that LTFU was associated 
with a 62% increased risk of stopping 
treatment early. Patients collected their TB 
medication monthly from the local primary 
healthcare clinic rather than from the 
spine clinic, so spine clinic LTFU did not 
automatically imply treatment termination. 
However, primary healthcare clinics may 
have stopped TB treatment after the 
conventional period of 6 months if there 
had not been additional communication 
from the hospital – a scenario that may help 
to explain the association between rapid 
LTFU from the spine clinic and <9 months 
of treatment. With the risk of premature 
treatment cessation in mind, it had become 
common practice for the spine specialist 
to use spine clinic follow-up visits to send 
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Fig. 2. Loss to spine clinic follow-up among all patients (A) and patients grouped by TB treatment 
duration (B). Blue shading indicates the minimum recommended treatment duration. (TB = tuberculosis; 
*Significant difference in the pattern of LTFU between patients completing <9 and ≥9 months of TB 
treatment (p<0.0001.)
Table 2. TB treatment outcomes, in total and by follow-up outcome
Total (N=150) LTFU (N=110) Retained (N=40) LTFU v. retained, p-value
TB medication duration (months), n (%)
<9 45 (30) 45 (41) 0 <0.0001
≥9 105 (70) 65 (59) 40 (100)
Who stopped TB treatment, n (%)
Orthopaedic specialist 54 (36) 26 (24) 28 (70) <0.0001
Other/unclear 96 (64) 84 (76) 12 (30)
LTFU = lost to follow-up from the spine clinic; Retained = retained in follow-up at the spine clinic; TB = tuberculosis.
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a letter with the patient to the primary healthcare clinic. This 
letter would confirm the longer treatment duration and request 
continuation with the four-drug regimen throughout treatment. In 
addition, at every spine clinic visit, patients were routinely counselled 
about their TB treatment and received feedback on an ESR test and 
spine radiograph conducted on the day. In this way, spine clinic 
follow-up may have helped to consolidate patient awareness of the 
longer treatment duration, encouraged adherence, and increased the 
likelihood of patient objection should the primary healthcare clinic 
initiate treatment termination. The finding that 60% of patients had 
no treatment outcome reported in the ETR.net may suggest some 
uncertainty in the treatment of spinal TB at primary healthcare level 
and further supports the benefit of spine clinic follow-up.
Although spine clinic LTFU may be linked with premature 
treatment cessation, the study was not able to identify any baseline 
variables predicting LTFU that could hence inform retention-in-
care strategies. While the lengthy study period and systematic 
inclusion of patients was intended to mitigate the low incidence of 
spinal TB, the study may yet have lacked statistical power to detect 
certain baseline associations. For example, previous studies have 
on some occasions shown that younger age,[21,23,29] male sex,[21,23,29,30] 
increased distance from the hospital[32,34] and less severe clinical 
presentation[29,31] were associated with poor follow-up outcomes. 
However, it is even more likely that baseline characteristics included 
in the current analysis explain less variation in LTFU than other, 
unmeasured variables – variables not reliably available through 
retrospective record review. For example, smoking,[28-30,32,33] substance 
abuse,[28,29,33,40] feeling well[24,40,41] and a low level of education[17,31,33,40] 
have all been linked with loss to follow-up in TB- and trauma-related 
studies. Furthermore, the previously identified role of low income or 
poverty[28,31] may be particularly important in the current population, 
most of whom come from a low socioeconomic background, are 
unable to work for extended periods of time, and may have to weigh 
the expense of travel to the hospital against competing costs such as 
food.[24] With this in mind, anecdotal evidence suggests that some 
patients may also be LTFU after choosing to return to family in other 
provinces while they recuperate. Finally, this study did not account 
for the role of health system factors in LTFU.[24,40] For example, the 
fact that 5 patients were not booked for a follow-up appointment 
at discharge and 33% of those LTFU had an appointment indicated 
in the follow-up plan but not booked on the patient administration 
system suggests that administrative factors may be associated with 
LTFU and warrant further investigation.
Study limitations
Notable limitations of the current study include its retrospective 
nature and variation in the quality and completeness of the routine 
health data on which it was based. Related to this was the fact that 
TB treatment start and end dates had to be determined using a 
hierarchy of evidence, as this information was not always available 
in the medical record. Differences in the source of treatment dates 
for each patient may have introduced some information bias into the 
study, as patients LTFU were more likely to have end of treatment 
determined by ETR.net or pharmacy records than those who were 
retained in spine clinic follow-up. Other limitations include the 
aforementioned constraints in statistical power and unmeasured 
explanatory variables. These limitations may explain why the study 
was not able to identify causes of LTFU. Furthermore, the study 
did not assess other primary, secondary and tertiary health system 
contacts over and above spine clinic follow-up, or relate the primary 
outcomes to clinical outcomes such as repeated hospital admissions 
or spinal TB recurrence in subsequent years. While this additional 
information fell beyond the scope of the study objectives, it may well 
have been valuable for interpretation of the findings. Strengths of the 
current study included collation of different sources for determining 
the primary outcomes – a strategy that allowed for less missing data 
and more patients included in the analysis. Furthermore, patients 
who were excluded on the basis of missing data showed similar 
characteristics to those who were included, suggesting a low risk of 
selection bias in the findings.
Conclusions
The present study demonstrated that 75% of patients with spinal TB 
did not complete follow-up at the tertiary hospital spine clinic and 
that almost one in three patients received less than the minimum 
9 months of TB treatment. The long-term outcome of these patients 
fell beyond the scope of the study, and the clinical significance of 
being LTFU and/or completing shorter treatment is unclear. It is 
likely that the required duration of TB treatment varies between 
individuals. However, in the absence of a feasible measure of clinical 
cure, extended treatment serves to err on the side of caution. The 
present study found that remaining in spine clinic follow-up was 
significantly associated with completing at least 9 months of TB 
treatment, and arguably supports the role of this monitoring under 
the present circumstances.
In the future, qualitative interviews of patients attending follow-up 
and LTFU could improve understanding of follow-up determinants 
and inform strategies for retaining patients in care. However, novel 
measures of clinical cure in spinal TB, suitable for use in the SA 
public health setting, should also be considered a research priority. 
Such measures may allow for more individualised, evidence-based 
treatment duration and decrease the overall burden of follow-up 
required. In time, these research findings could form an evidence 
base for new policy, improving both the treatment of spinal TB and 
use of health system resources.
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